Biocytogen Pharmaceuticals signs a License Agreement With Pheon Therapeutics
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a global biotech company focusing on the discovery of novel antibody therapeutics, yesterday announced an antibody license agreement with Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next-generation ADCs for a wide range of hard-to-treat cancers. Under the terms of the agreement, Pheon will develop and commercialize an […]
CRO company TriApex completes Series C financing round led by Legend Capital
TriApex Laboratories Co., Ltd recently announced the completion of its Series C financing round, which was led by Legend Capital. This funding milestone will help TriApex continue to lead in the field of special diseases and devote itself to providing non-clinical data with more clinical value, accelerating the international expansion of integrated R&D services from […]
Sofinnova Partners appoints Mary McCarthy as partner in charge of biotech strategy
Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the appointment of Mary McCarthy as Partner at Sofinnova Partners, joining the growing Sofinnova Industrial Biotech Strategy team. She will use her extensive experience and network to help identify the most promising early-stage companies developing biotech-enabled sustainable solutions in agriculture, […]
KBI Biopharma and Selexis SA announces J.D. Mowery as CEO
KBI Biopharma, Inc. (KBI) and Selexis SA, both JSR Life Sciences companies, recently announced the appointment of J.D. Mowery as Chief Executive Officer (CEO). Widely respected as an innovative biotech leader with a nearly 25-year track record of successfully inspiring colleagues and building organizations, J.D. will lead KBI and Selexis into the next chapter of […]
Immunis appoints Neil Sahota as Chief Artificial Intelligence Officer
Immunis, Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, has appointed Neil Sahota as its Chief Artificial Intelligence (AI) Officer. AI is a tool that is transforming the way businesses and scientists integrate information, conduct data analysis, and make informed decisions on how to optimize growth. For over […]
Tianlong unveils two new products for portable and on-site testing needs
Tianlong, an innovative high-tech company specializing in molecular diagnostic products, has announced the global release of two new products, the GeneFlex Nucleic Acid Extractor and the Gentier mini+ Real-time PCR System. Featuring compact design and portability, they can provide researchers and clinicians with reliable and efficient tools for nucleic acid extraction and real-time PCR applications. […]
Biostage appoints Mr Jerry He as CEO & Chairman
Biostage, a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastro-intestinal system and the airway resulting from cancer, trauma or birth defects, recently announced that effective as of March 1, 2023, its existing director since November 2021, Mr. Jerry He, was appointed Chairman of the Board and hired as Chief Executive Officer. Mr. He replaces David Green who is […]
Silence Therapeutics onboards J.P. Gabriel as CTOO
Silence Therapeutics plc, (“Silence” or “the Company”), One of the experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, recently announced the appointment of J.P. Gabriel as Chief Technical Operations Officer (CTOO) following the retirement of Jørgen Wittendorff, SVP, Technical Operations. In this role, J.P. is responsible […]
Aplantex onboards Patrick Charest as CEO
The board of directors of Aplantex is pleased to announce the nomination of Mr. Patrick Charest, B. Sc, P. Eng. as CEO of the company. With over 25 years of experience in supporting the growth of leading private sector organizations, Patrick is a dynamic and inspiring leader with a unique ability to envision and implement […]
Akston Biosciences appoints John T. Preston as Board of Directors
Akston Biosciences Corporation, one of the clinical-stage biotechnology company, recently announced that John T. Preston, a founder of TEM Capital, has joined its Board of Directors. A recipient of numerous awards and previous advisor to several government agencies and expert witness for Congress, Preston brings to Akston his decades of experience in technology commercialization and intellectual […]
